Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma

Overview

Journal Chest

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2015 Apr 4

PMID 25836013

Citations 32

Authors

Kyuichi Kadota

Yi-Chen Yeh

Jonathan Villena-Vargas

Leonid Cherkassky

Esther N Drill

Camelia S Sima

David R Jones

William D Travis

Prasad S Adusumilli

Affiliations

Soon will be listed here.

Abstract

Background: Immune cell infiltration associated with tumor capsule disruption and tumor budding has been shown to reflect invasiveness, metastasis, and unfavorable prognosis in colorectal cancer. We investigated the influence of tumor budding on prognosis and its association with the immune microenvironment in lung adenocarcinoma.

Methods: Tumor slides from resected stage I lung adenocarcinomas were reviewed (n = 524 and n = 514, for training and validation cohorts, respectively) for assessment of tumor budding. CD3+ and forkhead box P3+ (FoxP3+) lymphocytes, CD68+ macrophages, IL-7 receptor, and IL-12 receptor β2 were analyzed using tissue microarrays constructed from tumor and stroma. Probability of recurrence was calculated using the competing risks method.

Results: In the training cohort, risk of recurrence for high-grade tumor budding was higher than it was for low-grade tumor budding (32% vs 12%, P < .001), which was confirmed in the validation cohort (P = .005). Tumor budding stratified the risk of recurrence for acinar-predominant (22% vs 9%, P < .001), papillary-predominant (22% vs 13%, P = .045), and solid-predominant (39% vs 19%, P = .022) tumors. Tumor budding was associated with higher stromal FoxP3+ lymphocyte infiltration, higher stromal FoxP3/CD3 risk index, higher tumoral and stromal CD68+ macrophage infiltration, and IL-7 receptor overexpression (P < .001, all associations). Tumor budding remained independently associated with recurrence on multivariate analysis (hazard ratio, 1.61; P = .008).

Conclusions: Tumor budding is an independent prognostic factor of stage I lung adenocarcinoma and correlates with the protumor immune microenvironment. Our findings advocate investigating tumor-immune cell interactions at the invading edge as a biologic driver of tumor aggressiveness.

Citing Articles

Neoteric Predictors for Lymph Node Metastasis in Early Oral Squamous Cell Carcinoma: Tumor Budding and Worst Pattern of Invasion.

Singh A, Pradhan S, Kannan R, Lakshminarayan A, Kumar K, Shaikh M Indian J Otolaryngol Head Neck Surg. 2024; 76(6):5639-5646.

PMID: 39558984 PMC: 11569069. DOI: 10.1007/s12070-024-05050-7.

Study of tumor budding and its association with clinicopathological parameters in breast carcinoma.

Kaundiyal S, Chandra S, Arora A Rev Assoc Med Bras (1992). 2024; 70(7):e20240173.

PMID: 39166665 PMC: 11329258. DOI: 10.1590/1806-9282.20240173.

Tumor microenvironment characteristics association with clinical outcome in patients with resected intestinal-type gastric cancer.

Tian C, Jing H, Sinicrope F, Wang J, Gao B, Sun X Oncologist. 2024; 29(10):e1280-e1290.

PMID: 38907674 PMC: 11448893. DOI: 10.1093/oncolo/oyae124.

Prognostic Value of Tumor Budding for Early Breast Cancer.

Silva D, Miranda G, Amaro T, Salgado M, Mesquita A Biomedicines. 2023; 11(11).

PMID: 38001907 PMC: 10669365. DOI: 10.3390/biomedicines11112906.

Predictive value of tumor budding in head and neck squamous cell carcinoma: an update.

Chiesa-Estomba C, Thompson L, Agaimy A, Zidar N, Simpson R, Franchi A Virchows Arch. 2023; 483(4):441-449.

PMID: 37642731 DOI: 10.1007/s00428-023-03630-6.

References

Kadota K, Yeh Y, DAngelo S, Moreira A, Kuk D, Sima C . Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol. 2014; 38(8):1118-27. PMC: 4666292. DOI: 10.1097/PAS.0000000000000246. View

Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A . The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest. 2014; 146(3):633-643. DOI: 10.1378/chest.13-2499. View

Lewis D, Check D, Caporaso N, Travis W, Devesa S . US lung cancer trends by histologic type. Cancer. 2014; 120(18):2883-92. PMC: 4187244. DOI: 10.1002/cncr.28749. View

Satoh K, Nimura S, Aoki M, Hamasaki M, Koga K, Iwasaki H . Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met. Cancer Sci. 2014; 105(11):1487-95. PMC: 4462370. DOI: 10.1111/cas.12530. View

Puppa G, Senore C, Sheahan K, Vieth M, Lugli A, Zlobec I . Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology. 2012; 61(4):562-75. DOI: 10.1111/j.1365-2559.2012.04270.x. View

Yoshizawa A, Motoi N, Riely G, Sima C, Gerald W, Kris M . Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24(5):653-64. DOI: 10.1038/modpathol.2010.232. View

Asiedu M, Ingle J, Behrens M, Radisky D, Knutson K . TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 2011; 71(13):4707-19. PMC: 3129359. DOI: 10.1158/0008-5472.CAN-10-4554. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Zlobec I, Minoo P, Terracciano L, Baker K, Lugli A . Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology. 2011; 59(3):482-95. DOI: 10.1111/j.1365-2559.2011.03975.x. View

10.

Byrne W, Mills K, Lederer J, OSullivan G . Targeting regulatory T cells in cancer. Cancer Res. 2011; 71(22):6915-20. PMC: 4287207. DOI: 10.1158/0008-5472.CAN-11-1156. View

11.

Kadota K, Suzuki K, Colovos C, Sima C, Rusch V, Travis W . A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol. 2011; 25(2):260-71. PMC: 4080411. DOI: 10.1038/modpathol.2011.146. View

12.

Dignam J, Zhang Q, Kocherginsky M . The use and interpretation of competing risks regression models. Clin Cancer Res. 2012; 18(8):2301-8. PMC: 3328633. DOI: 10.1158/1078-0432.CCR-11-2097. View

13.

Chappell R . Competing risk analyses: how are they different and why should you care?. Clin Cancer Res. 2012; 18(8):2127-9. DOI: 10.1158/1078-0432.CCR-12-0455. View

14.

Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P . The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012; 30(13):1438-46. DOI: 10.1200/JCO.2011.37.2185. View

15.

Taira T, Ishii G, Nagai K, Yoh K, Takahashi Y, Matsumura Y . Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. Lung Cancer. 2011; 76(3):423-30. DOI: 10.1016/j.lungcan.2011.11.010. View

16.

Kadota K, Suzuki K, Kachala S, Zabor E, Sima C, Moreira A . A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol. 2012; 25(8):1117-27. PMC: 4382749. DOI: 10.1038/modpathol.2012.58. View

17.

Kadota K, Colovos C, Suzuki K, Rizk N, Dunphy M, Zabor E . FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol. 2012; 19(11):3598-605. PMC: 4049004. DOI: 10.1245/s10434-012-2414-3. View

18.

Mitrovic B, Schaeffer D, Riddell R, Kirsch R . Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012; 25(10):1315-25. DOI: 10.1038/modpathol.2012.94. View

19.

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F . Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2012; 8(1):52-61. DOI: 10.1097/JTO.0b013e3182769aa8. View

20.

Suzuki K, Kadota K, Sima C, Nitadori J, Rusch V, Travis W . Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2012; 31(4):490-8. PMC: 3731922. DOI: 10.1200/JCO.2012.45.2052. View